Astrazeneca's breast cancer drug fails late-stage trial
AstraZeneca announced on September 11, 2026, that an undisclosed breast cancer drug failed to meet the primary goal of improving progression-free survival (PFS) during a late-stage clinical trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.